An individual patient-based meta-analysis of tamoxifen versus ovarian ablation as first line endocrine therapy for premenopausal women with metastatic breast cancer
Tóm tắt
We performed a meta-analysis of randomized trials comparing tamoxifen to ovarian ablation carried out either by surgery or irradiation as first-line hormonal therapy for pre-menopausal women with metastatic breast cancer. Patients in all trials included were required to have measurable disease and to be currently menstruating or within 1 year of cessation of menses, and to have estrogen receptor (ER) positive or unknown disease (ER negative women were admitted to one of the studies). Individual patient data were obtained from the four studies identified and the results updated to June 1992. A total of 220 eligible patients were enrolled in the four trials. There was no difference in overall response rate between tamoxifen and oophorectomy across the four trials (p = 0.94, Mantel-Haenszel test). The odds reduction for progression was 14% ± 12% and for mortality 6% ± 13% in favour of tamoxifen, results which were not statistically significant (p = 0.32 and 0.72, respectively). Although the design of all four studies included a cross-over to the other therapy, only 54/111 patients receiving ovarian ablation and 34/109 patients receiving tamoxifen as primary therapy actually crossed over to the other arm at the time of disease progression. Response to initial treatment with tamoxifen was predictive of subsequent response to ovarian ablation (p < 0.05), and response to initial therapy with ovarian ablation was predictive of subsequent response to tamoxifen (p < 0.05). Support curves based on log-likelihood ratios revealed that this meta-analysis provides moderate evidence rejecting a 14% advantage for ovarian ablation compared to tamoxifen in terms of odds of disease progression. A 25% advantage for ovarian ablation with respect to odds of death is also rejected with moderate evidence. We conclude that the efficacy of tamoxifen appears to be similar to that of ovarian ablation by surgery or irradiation as first-line therapy for premenopausal, ER positive metastatic breast cancer, and is unlikely to be substantially inferior.
Tài liệu tham khảo
Ward HWC: Antioestrogen therapy for breast cancer: A trial of tamoxifen at two dose levels. Br Med J 1: 13-14, 1973
Pritchard KI, Thomson DB, Myers RE, Sutherland DJ: Tamoxifen therapy in premenopausal patients with metastatic breast cancer. Cancer Treat Rep 64: 787-796, 1989
Manni A, Jaime MD, Trujillo JE, Marshall JS, Brodkey J, Pearson OH: Antihormone treatment of stage IV breast cancer. Cancer 43: 444-450, 1979
Planting AS, Alexieva-Figusch J, Blonk VD, Wijst J, van Putten WL: Tamoxifen therapy in premenopausal women with metastatic breast cancer. Cancer 69: 363-368, 1985
Henderson IC, Canellos GP: Cancer of the breast: The past decade. New Engl J Med 302: 17-30, 1980
Conte CC, Nemoto T, Rosner D, Dao TL: Therapeutic oophorectomy in metastatic breast cancer. Cancer 64: 150-153, 1989
Sawka CA, Pritchard KJ, Paterson AHG, Sutherland DJ, Thomson DB, Shelley WE, Myers RE, Mobbs BG, Malkin A, Meakin JW: Role and mechanism of action of tamoxifen in premenopausal women with metastatic breast carcinoma. Cancer Res 46: 3152-3156, 1986
Hoogstraten B, Fletcher WS, Gad-el-Mawla N, Maloney T, Altman SJ, Vaughn CB, Foulkes MA: Tamoxifen and oophorectomy in the treatment of recurrent breast cancer. Cancer Res 4: 4788-4791, 1982
Ingle JN, Krook JE, Green SJ, Kubista TP, Everson LK, Ahmann DL, Chang MN, Bisel HF, Windschitl HE, Twito DI: Randomized trial of bilateral oophorectomy versus tamoxifen in premenopausal women with metastatic breast cancer. J Clin Oncol 4: 178-185, 1986
Buchanan RB, Blarney JRW, Durrant KR, Howell A, Paterson AG, Preece PE, Smith DC, Williams CJ, Wilson RG: A randomized comparison of tamoxifen with surgical oophorectomy in premenopausal patients with advanced breast cancer. J Clin Oncol 4: 1326-1330, 1986
Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, Mantel N, McPherson K, Peto J, Smith PG: Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II Analysis and examples. Br J Cancer 35: 1-39, 1977
Early Breast Cancer Trialists' Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy: 133 randomized trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 339: 1-15, 71–85, 1992
Early Breast Cancer Trialists' Collaborative Group: Treatment of Early Breast Cancer. Volume 1, Worldwide Evidence 1985–1990. Oxford University Press, Oxford
Mantel N: Chi-square tests with one degree of freedom; extensions of the Mantel-Haenszel procedure. Am Stat Assoc J 58: 690-700, 1963
Poole C: Beyond the confidence interval (different views). Am J Public Health 77: 195-199, 1987
Borenstein M: The case for confidence intervals in controlled clinical trials. Controlled Clinical Trials 15: 411-428, 1994
Goodman SN, Royall R: Evidence and scientific research. (Commentary) Am J Public Health 78: 1568-1574, 1988
Goodman SN: Meta-analysis and evidence. Controlled Clin Trials 10: 188-204, 1989 (see also published errata 1989; 10: 435)
Goodman SN: Pvalues, hypothesis tests, and likelihood: Implications for epidemiology of a neglected historical debate. (Reviews and Commentary) Am J Epidemiol 137: 485-496, 1993
Goodman SN, Berlin JA: The use of predicted confidence intervals when planning experiments and the misuse of power when interpreting results. Annals of Internal Medicine 121: 201-206, 1994. See also published correction 122: 478, 1995
Meakin JW, Allt WEC, Beale FA, Brown TC, Bush RS, Clark RM, Fitzpatrick PJ, Hawkins NV, Jenkin RD, Pringle JF, Reid JG, Rider WD, Hayward JL, Bulbrook RD: Ovarian irradiation and prednisone therapy following surgery and radiotherapy for carcinoma of the breast. Can Med Assoc J 19: 1221-1238, 1979
Taylor CW, Green S, Dalton WS, Martino S, Ingle JN, Robert NJ, Rector DJ, Osborne CK, Participating investigators of the Southwest Oncology Group, North Central Cancer Treatment Group and Eastern Cooperative Oncology Group: A multi-center randomized trial of Zoladex versus surgical ovariectomy in premenopausal patients with receptor positive metastatic breast cancer. Breast Cancer Res Treat 37: 31, 1995
Fisher B, Costantino J, Redmond C, Poisson R, Bowman D, Couture J, Dimitrov NV, Wolmark N, Wickerham DL, Fisher ER: A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen receptor-positive tumors. N Engl J Med 320: 479-484, 1989
Castiglione-Gertsch M, Johnsen C, Goldhirsch A, Gelber RD, Rudenstam CM, Collins J, Lindtner J, Hacking A, Cortes-Funes H, Forbes J: The International (Ludwig) Breast Cancer Study Group Trials I–IV: 15 years follow up. Ann Oncol 5: 717-724, 1994
Scottish Cancer Trials Breast Group: Adjuvant ovarian ablation versus CMF chemotherapy in premenopausal women with pathological stage II breast carcinoma: The Scottish trial. Lancet 341: 1293-1298, 1993
Personal Communication, Douglas Tormey: Eastern Cooperative Oncology Group Trial of EST 5188 of Cyclophosphamide, Doxorubicin and 5-Fluoro-Uracil ×6 vs same followed by Goserelin × 5 yr vs same followed by Goserelin plus tamoxifen × 5 yrs
Personal Communication, Aron Goldhirsch: International Breast Cancer Study Group Trial VIII. CMF × 5 mos vs. Goserelin × 2 yrs vs CMF × 5 mos followed by Goserelin × 18 mos
Personal Communication, Kent Osborne: South West Oncology Group Trial of CMFVP vs CMFVP plus oophorectomy, study 7827
Personal Communication, Michael Baum: UKCC CR National Adjuvant Breast Cancer Trial of Ovarian Suppression vs control vs chemotherapy vs both
Colditz GA, Willett WC, Stampfer MJ, Rosner B, Speizer FE, Hennekens CH: Menopause and the risk of coronary heart disease in women. N Engl J Med 316: 1105-1110, 1987
Knoweldon J, Buhr AJ, Dunbar O: Incidence of fractures in persons over 35 years of age: A report to the M.R.C. working party on fractures in the elderly. Br J Prev Soc Med 18: 130-141, 1964
McDonald CC, Stewart HJ for the Scottish Breast Cancer Committee: Brit Med J 303: 435-437, 1991
Rutqvist LE, Mattson A: Cardiac and thromboembolic morbidity among postmenopausal women with early stage breast cancer in a randomized trial of adjuvant tamoxifen. J Natl Cancer Inst 87: 645-651, 1995
Love RR, Mazess RB, Barden HS, Epstein S, Newcomb PA, Jordan VC, Carbone PP, DeMets DL: Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 326: 852-856, 1992
Osborne CK, Kitten L, Arteaga CL: Antagonism of chemotherapy-induced cytotoxicity for human breast cancer cells by antiestrogens. J Clin Oncol 7: 710-717, 1989
Goldenberg GJ, Froese EK: Antagonism of the cytocidal activity and uptake of melphalan by tamoxifen in human breast cancer cells in vitro. Biochem Pharmacol 34: 763-770, 1985
Personal Communication, Vivien Bramwell: National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) Clinical Trial MA.12. A double-blind randomized trial of tamoxifen versus placebo in patients with node positive or high risk node negative breast cancer who have completed CMF, CEF or AC adjuvant chemotherapy
Personal Communication, P.F. Bruning: European Organization for Research and Treatment of Cancer (EORTC) Breast Cancer Cooperative Group Trial # 10901. Postoperative adjuvant chemotherapy followed by adjuvant tamoxifen versus nil for patients with operable breast cancer
Personal Communication, Aron Goldhirsch: International Breast Cancer Study Group Trial 13. A trial of adjuvant therapy for premenopausal patients with node positive breast cancer who are not suitable for endocrine therapy alone
Personal Communication, C Kent Osborne: South West Oncology Group. Trial of tamoxifen versus no therapy following CMF or CAF chemotherapy in high risk node negative premenopausal women